1-(5,6-二甲基-1H-苯并咪唑-2-基)-N-甲基甲胺 | 938458-93-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 中文名称: 1-(5,6-二甲基-1H-苯并咪唑-2-基)-N-甲基甲胺
• 英文名称: N-[(5,6-dimethyl-1H-benzimidazol-2-yl)methyl]-N-methylamine
• 英文别名: 1-(5,6-dimethyl-1H-benzimidazol-2-yl)-N-methylmethanamine
• CAS: 938458-93-6
• 化学式: C₁₁H₁₅N₃
• mdl: MFCD09055241
• 分子量: 189.26
• InChiKey: JRKQGSCJUPQTJJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  40.7
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933990090

文献信息

• HETEROCYCLIC ACETAMIDE COMPOUND
  申请人：ASTELLAS PHARMA INC.

  公开号：US20140315963A1

  公开（公告）日：2014-10-23

  [Problem] A compound which is useful as a dopamine D1 receptor positive allosteric modulator (D1 PAM) is provided. [Means for Solution] The present inventors have studied a compound which has a dopamine D1 receptor positive allosteric modulating activity and is useful as an active ingredient of a pharmaceutical composition for preventing and/or treating cognitive impairment, negative symptoms of schizophrenia, Parkinson's disease, Alzheimer's disease, Huntington's disease, drug addictions, or the like, and they have thus found that a heterocyclic acetamide compound has a dopamine D1 receptor positive allosteric modulating activity, thereby completing the present invention. The heterocyclic acetamide compound of the present invention has a dopamine D1 receptor positive allosteric modulating activity and can be used as an agent for preventing and/or treating cognitive impairment, negative symptoms of schizophrenia, Parkinson's disease, Alzheimer's disease, Huntington's disease, drug addictions, or the like.

  [问题] 提供了一种作为多巴胺D1受体正变构调节剂（D1 PAM）有用的化合物。 [解决方案] 本发明的发明人已经研究了一种具有多巴胺D1受体正变构调节活性的化合物，该化合物作为用于预防或治疗认知障碍、精神分裂症阴性症状、帕金森病、阿尔茨海默病、亨廷顿病、药物成瘾等的药物组合物的有效成分是有用的，他们因此发现了一种杂环乙酰胺化合物具有多巴胺D1受体正变构调节活性，从而完成了本发明。本发明的杂环乙酰胺化合物具有多巴胺D1受体正变构调节活性，并且可以用作预防或治疗认知障碍、精神分裂症阴性症状、帕金森病、阿尔茨海默病、亨廷顿病、药物成瘾等的药剂。
• TRIAZINE COMPOUNDS AND USES THEREOF
  申请人：Aduro BioTech, Inc.

  公开号：EP3810600A1

  公开（公告）日：2021-04-28
• Triazine Compounds and Uses Thereof
  申请人：Aduro Biotech, Inc.

  公开号：US20210246122A1

  公开（公告）日：2021-08-12

  The present invention relates to triazine compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating autoimmune, inflammatory, and neurodegenerative diseases by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.
• US8937087B2
  申请人：——

  公开号：US8937087B2

  公开（公告）日：2015-01-20
• US9708307B2
  申请人：——

  公开号：US9708307B2

  公开（公告）日：2017-07-18